UCB in brief

In just three years, UCB realised two major acquisitions - Celltech and Schwarz Pharma - which propelled UCB to become a global biopharmaceutical company with one of the richest late stage pipelines.

• A global biopharma leader focused on severe diseases, with operations in more than 40 countries and global revenue of more than €3.6 billion in 2007.
  
  
• The leader in allergy and epilepsy, with twelve new large and small molecules in the pipeline, spanning sixteen diseases, from Crohn’s and Parkinson’s disease to multiple sclerosis.
  
  
• A leader in antibody research, supported by proprietary chemistry and over 30 major R&D partners.